Influenza Centre, The Gade Institute, University of Bergen, N-5021 Bergen, Norway.
Vaccine. 2009 Dec 9;27(52):7367-76. doi: 10.1016/j.vaccine.2009.09.044. Epub 2009 Sep 23.
Ideally, a candidate pandemic influenza vaccine should elicit rapid and strong cell-mediated and humoral immune responses, which are long-lasting and exhibit broad cross-reactivity against drifted strains. The present study investigated the detailed humoral and cellular immune responses in mice vaccinated intranasally or intramuscularly with inactivated influenza H5N1 (NIBRG-14) virosomal vaccine alone or formulated with Matrix-M adjuvant. The intramuscular Matrix-M-adjuvanted vaccine induced a strong immediate and long-term humoral immune response with high cross-reactivity against drifted H5N1 viruses and showed a dose-sparing potential. Additionally, the vaccine induced a balanced Th1/Th2 cytokine profile and most importantly high frequencies of multifunctional Th1 CD4(+) cells. Our results highlight that Matrix-M adjuvant is a promising parenteral adjuvant for formulating pandemic candidate vaccines.
理想情况下，候选大流行性流感疫苗应能迅速引发强烈的细胞介导和体液免疫应答，且应答具有持久性，并对漂移株表现出广泛的交叉反应性。本研究调查了经鼻内或肌肉内接种用灭活的 H5N1（NIBRG-14）病毒体疫苗单独或与 Matrix-M 佐剂配制的流感病毒疫苗的小鼠的详细体液和细胞免疫应答。肌肉内 Matrix-M 佐剂疫苗可诱导迅速和长期的体液免疫应答，对漂移的 H5N1 病毒具有高交叉反应性，并显示出节省剂量的潜力。此外，该疫苗诱导出平衡的 Th1/Th2 细胞因子谱，最重要的是诱导出高频率的多功能 Th1 CD4(+)细胞。我们的研究结果表明，Matrix-M 佐剂是一种很有前途的可用于配制大流行候选疫苗的新型佐剂。
